XML 68 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Sales (Details) - USD ($)
$ in Thousands
12 Months Ended
Mar. 04, 2023
Feb. 26, 2022
Feb. 27, 2021
Product Class      
Revenues $ 24,091,899 $ 24,568,255 $ 24,043,240
Intersegment eliminations      
Product Class      
Revenues (215,467) (249,686) (292,157)
Front end sales      
Product Class      
Revenues 5,078,820    
Retail Pharmacy Segment      
Product Class      
Other revenue 123,654 124,143 126,875
Revenues 17,785,067 17,494,816 16,365,260
Retail Pharmacy Segment | Pharmacy sales      
Product Class      
Revenues 12,582,593 12,152,491 10,915,442
Retail Pharmacy Segment | Front end sales      
Product Class      
Revenues $ 5,078,820 $ 5,218,182 $ 5,322,943
Retail Pharmacy Segment | Prescription drugs | Revenue from Contract with Customer, Segment Benchmark [Member] | Product Concentration Risk [Member]      
Product Class      
Percentage of sales 71.20% 70.00% 66.70%
Retail Pharmacy Segment | Over-the-counter medications and personal care | Revenue from Contract with Customer, Segment Benchmark [Member] | Product Concentration Risk [Member]      
Product Class      
Percentage of sales 10.90%    
Retail Pharmacy Segment | Health and beauty aids | Revenue from Contract with Customer, Segment Benchmark [Member] | Product Concentration Risk [Member]      
Product Class      
Percentage of sales 4.30%    
Retail Pharmacy Segment | General merchandise and other | Revenue from Contract with Customer, Segment Benchmark [Member] | Product Concentration Risk [Member]      
Product Class      
Percentage of sales 13.60%    
Pharmacy Services Segment      
Product Class      
Revenues $ 6,522,299 $ 7,323,125 $ 7,970,137
Pharmacy Services Segment | Pharmacy sales      
Product Class      
Revenues $ 12,582,593